The National Research Council (NRC) in Canada has awarded ContraVir Pharmaceuticals more than $224,000  to cover expenses related to the preclinical development of CRV431, the company’s cyclophilin inhibitor for the treatment of hepatitis B virus (HBV). The research award, ... Read more